United Therapeutics CEO Exercises Options and Sells 9,500 Shares via 10b5-1 Plan

Executive Summary

On October 6, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed stock options for 9,500 shares of common stock at an exercise price of $117.76 and immediately sold the underlying shares across multiple tranches at weighted average prices ranging from $527.90 to $545.50. The aggregated sale generated approximately $5.12 million in gross proceeds.

Key Transaction Details

• Nature of Transaction: Option exercise (Code M) and same-day open market sale (Code S).
• Rule 10b5-1 Plan: Conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan covers the exercise of up to 1,734,410 stock options expiring March 15, 2027, or concludes on December 31, 2026.
• Volume & Value: 9,500 shares disposed of at an average execution price of approximately $538.70 per share, totaling roughly $5.12 million against an option strike price cost of $1.12 million.
• Post-Transaction Holdings: Rothblatt continues to retain significant exposure to United Therapeutics, holding 40,513 shares directly, over 628,000 shares across several family trusts, and 290,410 options remaining in this specific grant tranche.

Trading Significance

The trading significance is rated Low. The transactions represent a structured, pre-planned option monetization program pursuant to a Rule 10b5-1 plan established nearly a year prior. Because the sale involves options approaching expiration and Rothblatt maintains substantial equity ownership, this activity does not suggest a discretionary change in executive sentiment.